Atirmociclib vs SHR-6209
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 · full HR+/HER2- Metastatic Breast Cancer pipeline
Atirmociclib
Developed by Pfizer
NCT06465368 · Phase 2 · completed
The study randomized 121 participants to PF-07220060 plus letrozole or letrozole alone, but it was open-label, with only the biopsy assessment performed centrally in a blinded manner. Its primary endpoint was a Ki-67-based biomarker rather than a clinical outcome, and although the reported percentages favored the combination, statistical significance for the primary comparison was not stated.
Next expected readout: December 2026 · NCT06239467 (registry estimate)
Reported efficacy
Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8) (unclear)
Result source: NCT06465368
SHR-6209
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06974929 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Atirmociclib | SHR-6209 |
|---|---|---|
| PFS, median | —Trial running · NCT06760637 | —Trial running · NCT07894328 |
| OS, median | —Trial running · NCT06760637 | —Trial running · NCT07894328 |
| ORR | —Trial running · NCT06760637 | —Trial running · NCT07894328 |
| Clinical benefit rate | —Trial running · NCT06760637 | —Trial running · NCT07894328 |
PFS, median
- Atirmociclib
- —Trial running · NCT06760637
- SHR-6209
- —Trial running · NCT07894328
OS, median
- Atirmociclib
- —Trial running · NCT06760637
- SHR-6209
- —Trial running · NCT07894328
ORR
- Atirmociclib
- —Trial running · NCT06760637
- SHR-6209
- —Trial running · NCT07894328
Clinical benefit rate
- Atirmociclib
- —Trial running · NCT06760637
- SHR-6209
- —Trial running · NCT07894328
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SHR-6209: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Atirmociclib: 3 of 4 rows · SHR-6209: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Atirmociclib |
|---|---|
| Dropout rate | 0%a NCT06465368 · Phase 2 · combination |
| Discontinued due to AEs | —a NCT06465368 · Phase 2 · combination |
| Serious AEs | 1.7%a NCT06465368 · Phase 2 · combination |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Atirmociclib
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atirmociclib's landscape · SHR-6209's landscape